[ad_1]
Shapiro, A. M., Pokrywczynska, M. & Ricordi, C. Scientific pancreatic islet transplantation. Nat. Rev. Endocrinol. 13, 268–277 (2017).
Molano, R. D. et al. Lengthy-term islet allograft survival in nonobese diabetic mice handled with tacrolimus, rapamycin, and anti-interleukin-2 antibody. Transplantation 75, 1812–1819 (2003).
Shapiro, A. M. et al. Islet transplantation in seven sufferers with kind 1 diabetes mellitus utilizing a glucocorticoid-free immunosuppressive routine. N. Engl. J. Med. 343, 230–238 (2000).
Rapamune (sirolimus) [Package Insert]. Wyeth Prescription drugs, Collegeville, PA (2011).
Halloran, P. F. Immunosuppressive medicine for kidney transplantation. N. Engl. J. Med. 351, 2715–2729 (2004).
Yatscoff, R. W., Wang, P., Chan, Okay., Hicks, D. & Zimmerman, J. Rapamycin: distribution, pharmacokinetics, and therapeutic vary investigations. Ther. Drug Monit. 17, 666–671 (1995).
Ferron, G. M., Mishina, E. V., Zimmerman, J. J. & Jusko, W. J. Inhabitants pharmacokinetics of sirolimus in kidney transplant sufferers. Clin. Pharmacol. Ther. 61, 416–428 (1997).
Meier-Kriesche, H. U. & Kaplan, B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin. Ther. 22, B93–B100 (2000).
Hafiz, M. M. et al. Immunosuppression and procedure-related problems in 26 sufferers with kind 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 80, 1718–1728 (2005).
Lombardi, G. & Vasquez, Y. in Handbook of Experimental Pharmacology, Vol. 188 (eds Lombardi, G. & Vasquez, Y.) Preface (Springer, 2009).
Stabler, C. L., Li, Y., Stewart, J. M. & Keselowsky, B. C. Engineering immunomodulatory biomaterials for kind 1 diabetes. Nat. Rev. Mater. 4, 429–450 (2019).
Emoto, C., Fukuda, T., Cox, S., Christians, U. & Vinks, A. A. Improvement of a physiologically-based pharmacokinetic mannequin for sirolimus: predicting bioavailability based mostly on intestinal CYP3A content material. CPT Pharmacometrics Syst. Pharmacol. 2, e59 (2013).
Haeri, A., Osouli, M., Bayat, F., Alavi, S. & Dadashzadeh, S. Nanomedicine approaches for sirolimus supply: a assessment of pharmaceutical properties and preclinical research. Artif. Cells Nanomed. Biotechnol. 46, 1–14 (2018).
Alemdar, A. Y., Baker, Okay. A., Sadi, D., McAlister, V. C. & Mendez, I. Liposomal tacrolimus administered systemically and throughout the donor cell suspension improves xenograft survival in hemiparkinsonian rats. Exp. Neurol. 172, 416–424 (2001).
Haeri, A. et al. Use of distant movie loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for therapy of restenosis. Int. J. Pharm. 414, 16–27 (2011).
Allen, S., Osorio, O., Liu, Y. G. & Scott, E. Facile meeting and loading of theranostic polymersomes by way of multi-impingement flash nanoprecipitation. J. Management. Launch 262, 91–103 (2017).
Allen, S. D. et al. Polymersomes scalably fabricated by way of flash nanoprecipitation are non-toxic in non-human primates and affiliate with leukocytes within the spleen and kidney following intravenous administration. Nano Res. https://doi.org/10.1007/s12274-018-2069-x (2018).
Stano, A., Scott, E. A., Dane, Okay. Y., Swartz, M. A. & Hubbell, J. A. Tunable T cell immunity in the direction of a protein antigen utilizing polymersomes vs. solid-core nanoparticles. Biomaterials 34, 4339–4346 (2013).
Scott, E. A. et al. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 33, 6211–6219 (2012).
Dowling, D. J. et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating results of the dwell BCG vaccine and improve neonatal innate and adaptive immune responses. J. Allergy Clin. Immunol. 140, 1339–1350 (2017).
Yi, S. et al. Tailoring nanostructure morphology for enhanced focusing on of dendritic cells in atherosclerosis. ACS Nano 10, 11290–11303 (2016).
Bracho-Sanchez, E., Hassanzadeh, A., Brusko, M. A., Pockets, M. A. & Keselowsky, B. G. Dendritic cells handled with exogenous indoleamine 2,3-dioxygenase keep an immature phenotype and suppress antigen-specific T cell proliferation. J. Immunol. Regen. Med. https://doi.org/10.1016/j.regen.2019.100015 (2019).
Peng, Y., Latchman, Y. & Elkon, Okay. B. Ly6Clow monocytes differentiate into dendritic cells and cross-tolerize T cells via PDL-1. J. Immunol. 182, 2777–2785 (2009).
Allen, R. P., Bolandparvaz, A., Ma, J. A., Manickam, V. A. & Lewis, J. S. Latent, immunosuppressive nature of poly(lactic-co-glycolic acid) microparticles. ACS Biomater. Sci. Eng. 4, 900–918 (2018).
Zhang, N. et al. Sirolimus is related to lowered islet engraftment and impaired β-cell operate. Diabetes 55, 2429–2436 (2006).
Rosborough, B. R. et al. Adenosine triphosphate-competitive mTOR inhibitors: a brand new class of immunosuppressive brokers that inhibit allograft rejection. Am. J. Transpl. 14, 2173–2180 (2014).
van den Bosch, T. P., Kannegieter, N. M., Hesselink, D. A., Baan, C. C. & Rowshani, A. T. Focusing on the monocyte-macrophage lineage in strong organ transplantation. Entrance. Immunol. 8, 153 (2017).
Abbas, A. Okay. & Lichtman, A. H. Fundamental Immunology: Features and Problems of the Immune System 2nd edn (Saunders, 2004).
Cantarelli, E. et al. Murine animal fashions for preclinical islet transplantation: no mannequin suits all (analysis functions). Islets 5, 79–86 (2013).
Mahe, E. et al. Cutaneous antagonistic occasions in renal transplant recipients receiving sirolimus-based remedy. Transplantation 79, 476–482 (2005).
Ventola, C. L. Progress in nanomedicine: accredited and investigational nanodrugs. P T 42, 742–755 (2017).
Burrack, A. L., Martinov, T. & Fife, B. T. T cell-mediated beta cell destruction: autoimmunity and alloimmunity within the context of kind 1 diabetes. Entrance. Endocrinol. (Lausanne) 8, 343 (2017).
Bouhdoud, L., Villain, P., Merzouki, A., Arella, M. & Couture, C. T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV) gp120-specific CD4+ cytotoxic T-cell clone, induced by a pure HIV kind 1 variant peptide. J. Virol. 74, 2121–2130 (2000).
Vieyra-Lobato, M. R., Vela-Ojeda, J., Montiel-Cervantes, L., Lopez-Santiago, R. & Moreno-Lafont, M. C. Description of CD8+ regulatory T lymphocytes and their particular intervention in graft-versus-host and infectious ailments, autoimmunity, and most cancers. J. Immunol. Res. 2018, 3758713 (2018).
Fu, C. et al. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to traditional dendritic cells via exosomes. Proc. Natl Acad. Sci. USA 117, 23730–23741 (2020).
Thomas, H. E., Darwiche, R., Corbett, J. A. & Kay, T. W. Interleukin-1 plus γ-interferon-induced pancreatic β-cell dysfunction is mediated by β-cell nitric oxide manufacturing. Diabetes 51, 311–316 (2002).
Kawamura, S. & Ohteki, T. Monopoiesis in people and mice. Int. Immunol. 30, 503–509 (2018).
Zhu, J., Chen, H., Huang, X., Jiang, S. & Yang, Y. Ly6Chello monocytes regulate T cell responses in viral hepatitis. JCI Perception 1, e89880 (2016).
Parrot, T. et al. Transcriptomic options of tumour-infiltrating CD4lowCD8excessive double constructive ɑβ T cells in melanoma. Sci. Rep. 10, 5900 (2020).
Parel, Y. et al. Presence of CD4+CD8+ double-positive T cells with very excessive interleukin-4 manufacturing potential in lesional pores and skin of sufferers with systemic sclerosis. Arthritis Rheum. 56, 3459–3467 (2007).
Overgaard, N. H., Jung, J. W., Steptoe, R. J. & Wells, J. W. CD4+/CD8+ double-positive T cells: greater than only a developmental stage? J. Leukoc. Biol. 97, 31–38 (2015).
Dew, M. A. et al. Charges and danger elements for nonadherence to the medical routine after grownup strong organ transplantation. Transplantation 83, 858–873 (2007).
Nulojix (belatacept) [Package Insert]. Bristol Myers Squibb, Princeton, NJ (2011).
O’Hare, F. M. et al. Neutrophil and monocyte toll-like receptor 4, CD11b and reactive oxygen intermediates, and neuroimaging outcomes in preterm infants. Pediatr. Res. 78, 82–90 (2015).
Yasunami, Y. et al. Vɑ14 NK T cell-triggered IFN-γ manufacturing by Gr-1+CD11b+ cells mediates early graft lack of syngeneic transplanted islets. J. Exp. Med. 202, 913–918 (2005).
Manzoli, V. et al. Immunoisolation of murine islet allografts in vascularized websites via conformal coating with polyethylene glycol. Am. J. Transpl. 18, 590–603 (2018).
Allen, S. D., Bobbala, S., Karabin, N. B., Modak, M. & Scott, E. A. Benchmarking bicontinuous nanospheres in opposition to polymersomes for in vivo biodistribution and twin intracellular supply of lipophilic and water-soluble payloads. ACS Appl. Mater. Interfaces 10, 33857–33866 (2018).
Yu, Y. R. et al. A protocol for the excellent move cytometric evaluation of immune cells in regular and infected murine non-lymphoid tissues. PLoS ONE 11, e0150606 (2016).
Belkina, A. C. et al. Automated optimized parameters for T-distributed stochastic neighbor embedding enhance visualization and evaluation of huge datasets. Nat. Commun. 10, 5415 (2019).
Andrews, S. FastQC: a top quality management device for prime throughput sequence knowledge. http://www.bioinformatics.babraham.ac.uk/initiatives/fastqc (Babraham Bioinformatics, 2010).
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a versatile trimmer for Illumina sequence knowledge. Bioinformatics 30, 2114–2120 (2014).
Dobin, A. et al. STAR: ultrafast common RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Trapnell, C. et al. Transcript meeting and quantification by RNA-seq reveals unannotated transcripts and isoform switching throughout cell differentiation. Nat. Biotechnol. 28, 511–515 (2010).
Trapnell, C. et al. Differential evaluation of gene regulation at transcript decision with RNA-seq. Nat. Biotechnol. 31, 46–53 (2013).
Roberts, A., Trapnell, C., Donaghey, J., Rinn, J. L. & Pachter, L. Enhancing RNA-seq expression estimates by correcting for fragment bias. Genome Biol. 12, R22 (2011).
[ad_2]
